Shares of Edgewise Therapeutics, Inc. (EWTX) surged 5.33% in the pre-market session on Friday, as analysts expressed optimism about the healthcare company's prospects.
Scotiabank initiated coverage on EWTX with an Outperform rating and a $50 price target, citing expectations of positive momentum for the company. The firm believes that Edgewise Therapeutics' pipeline and potential in the healthcare sector could drive significant growth in the future.
The positive analyst sentiment has boosted investor confidence in EWTX, leading to the stock's pre-market rally. As more analysts weigh in on the company, the market's outlook on Edgewise Therapeutics may continue to improve, potentially supporting further upward movement in the stock price.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。